Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

11/14/24 1:22:39 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CCCC alert in real time by email

SC 13G/A 1 cccc13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) C4 THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 12529R107 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 392,004 6. Shared Voting Power* 0 7. Sole Dispositive Power* 392,004 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 392,004 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 0.6% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: C4 THERAPEUTICS INC Item 1(b) Address of Issuer's Principal Executive Offices: 490 ARSENAL WAY, SUITE 120, WATERTOWN, MASSACHUSETTS 02472 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 12529R107 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: November 14, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 09/30/2024

Get the next $CCCC alert in real time by email

Recent Analyst Ratings for

$CCCC

Date	Price Target	Rating	Analyst
12/19/2024	$8.00 → $12.00	Equal Weight → Overweight	Wells Fargo
11/18/2024	$4.00	Equal-Weight	Stephens
1/29/2024	$6.00	Underweight → Neutral	JP Morgan
12/13/2023	$2.00 → $12.00	Hold → Buy	Stifel
2/24/2023	$12.00 → $10.00	Underperform → Neutral	Credit Suisse
2/24/2023	$15.00 → $5.00	Neutral → Underweight	JP Morgan
11/4/2022	$22.00 → $15.00	Overweight → Neutral	JP Morgan
10/11/2022	$6.00	Underweight	Morgan Stanley

More analyst ratings

Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$CCCC

$CCCC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

C4 Therapeutics upgraded by Wells Fargo with a new price target

Stephens initiated coverage on C4 Therapeutics with a new price target

C4 Therapeutics upgraded by JP Morgan with a new price target

$CCCC
SEC Filings

C4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

C4 Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

C4 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$CCCC
Press Releases

Fastest customizable press release news feed in the world

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

$CCCC
Financials

Live finance-specific insights

C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

$CCCC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Hoerter Steven L.

SEC Form 3 filed by new insider Hoerter Steven L.

Chief Legal Officer Siegel Jolie converted options into 3,750 shares and covered exercise/tax liability with 1,102 shares, increasing direct ownership by 5% to 56,488 units (SEC Form 4)

$CCCC
Large Ownership Changes

This live feed shows all institutional transactions in real time.